Orange Book product · Generic (ANDA)
BLEOMYCIN SULFATE
BLEOMYCIN SULFATE
At a glance
Oct 17, 2001
Approved
Generic (ANDA)
Application
AP
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Oct 17, 2001
25 yr ago
Today
Pharmaceutical detail
Active ingredient
BLEOMYCIN SULFATE
Strength
EQ 15 UNITS BASE/VIAL
Dosage form
INJECTABLE
Route
INJECTION
TE code
AP
Application
ANDA 065042
Product number
002
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of BLEOMYCIN SULFATE
- —BLENOXANEBrand (NDA)
NDA 050443 · BRISTOL MYERS SQUIBB
- 2019BLEOMYCIN SULFATEGeneric (ANDA)
ANDA 209439 · CIPLA
- 2018BLEOMYCIN SULFATEGeneric (ANDA)
ANDA 205030 · MEITHEAL
- 2008BLEOMYCIN SULFATEGeneric (ANDA)
ANDA 065185 · FRESENIUS KABI USA
- 2007BLEOMYCIN SULFATEGeneric (ANDA)
ANDA 065201 · PHARMACHEMIE BV
- 2000BLEOMYCIN SULFATEGeneric (ANDA)
ANDA 065033 · TEVA PHARMS USA
- 2000BLEOMYCIN SULFATEGeneric (ANDA)
ANDA 065031 · HOSPIRA
- 1996BLEOMYCIN SULFATEGeneric (ANDA)
ANDA 064084 · TEVA PARENTERAL
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
